Forest Labs, Gedeon Reports Phase III Results From Trial Of Cariprazine - NASDAQ

Forest Labs, Gedeon Reports Phase III Results From Trial Of Cariprazine NASDAQ (RTTNews.com) - Forest Laboratories, Inc. (FRX) and Gedeon Richter Plc announced preliminary top-line results from a Phase III clinical trial of cariprazine, an investigational antipsychotic agent, in patients with acute mania associated with bipolar I ... Forest Laboratories, Inc. and Gedeon Richter Plc Announce Positive Phase III ...MarketWatch (press release) all 10 news articles »

Race and mental illness: Do African Americans suffer more schizophrenia or is ... - Los Angeles Times

Race and mental illness: Do African Americans suffer more schizophrenia or is ... Los Angeles Times When a patient arrives in a clinic speaking incoherently, beset by delusions or hallucinations, and either severely withdrawn or manic, schizophrenia is a distinct possibility. But sometimes those same symptoms point to extreme cases of depression or ... and more »